Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Keros Therapeutics, Inc. (Nasdaq: KROS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Keros’ clinical programs, capital allocation decisions, governance changes and financial condition.
As a clinical-stage biopharmaceutical company focused on TGF-ß pathway therapeutics, Keros uses its SEC filings to report material events related to its lead product candidate KER-065 and its most advanced candidate elritercept. Form 8-K reports have covered topics such as additional clinical data from a Phase 1 trial of KER-065, U.S. Food and Drug Administration Orphan Drug designation for KER-065 in Duchenne muscular dystrophy, and corporate updates regarding the prioritization of KER-065 and discontinuation of internal development of cibotercept (KER-012).
Filings also document Keros’ capital return program and share repurchase activity. Recent 8-Ks describe stock purchase agreements with entities affiliated with ADAR1 Capital Management and Pontifax Venture Capital, the planned and completed cash tender offer to repurchase a substantial number of shares of common stock at a fixed price, and related governance changes. Other reports furnish quarterly financial results, including revenue from a global license agreement with Takeda Pharmaceuticals U.S.A., Inc. related to elritercept, research and development spending and cash and cash equivalents.
On this page, users can review real-time updates as new KROS filings are posted to EDGAR, including Forms 8-K, 10-Q and 10-K when available, as well as exhibits such as press releases and corporate presentations. Stock Titan’s AI-powered tools summarize lengthy filings, highlight key sections and help explain complex topics like capital return structures, executive employment agreements and risk factor disclosures in more accessible language.
For those analyzing Keros’ development strategy, financial runway, licensing arrangements or governance, the SEC filings page serves as a primary source of company-sanctioned information. It allows investors and researchers to trace how Keros reports progress on its TGF-ß–focused pipeline, documents material agreements and communicates significant corporate events over time.
Keros Therapeutics Schedule 13G reports that BlackRock, Inc. beneficially owned 1,990,842 shares of common stock, representing 10.1% of the class as of 03/31/2026. The filing attributes ownership to certain Reporting Business Units of BlackRock and shows 1,960,306 shares with sole voting power.
The filing states that various persons may have rights to dividends or sale proceeds and that no single outside person holds more than 5% separately. The filing is signed by a BlackRock managing director on 04/07/2026.
Keros Therapeutics chief executive officer Jasbir Seehra exercised employee stock options to acquire 55,000 shares of common stock at an exercise price of $0.30 per share on April 2, 2026. These options were immediately exercisable. Following the transaction, he directly owned 440,708 shares of common stock.
Keros Therapeutics reported that Chief Legal Officer Esther Cho received a grant of employee stock options covering 80,000 shares of common stock. The options have an exercise price of $15.52 per share and expire on February 23, 2036. One quarter of the options vest on February 24, 2027, with the remaining shares vesting in twelve substantially equal quarterly installments, contingent on her continued service. This is a compensation-related award rather than an open‑market purchase.
Keros Therapeutics Inc — Schedule 13G/A amendment filed by The Vanguard Group. The amendment states that, after an internal realignment under SEC Release No. 34-39538, The Vanguard Group reports 0 shares beneficially owned, representing 0% of Keros common stock. The filing explains certain subsidiaries will report holdings separately.
Keros Therapeutics director Charles W. Newton received new equity awards. He was granted stock options covering 14,788 shares of Common Stock at an exercise price of $11.35 per share, expiring on March 8, 2036, and 13,215 restricted stock units.
The RSUs vest over three years in twelve equal quarterly installments starting on May 15, 2026, while the options vest over three years in equal quarterly installments starting on June 9, 2026, in each case subject to his continuous service. Following these awards, he directly holds 14,788 options and 13,215 shares.
Keros Therapeutics, Inc. director Charles W. Newton has filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider of the company and records his starting position for future ownership and transaction disclosures.
Keros Therapeutics director Jean Jacques Bienaime bought 2,000 shares of common stock in an open-market transaction. The purchase took place on March 9, 2026 at a weighted average price of $11.21 per share, with individual trade prices ranging from $10.98 to $11.48. Following this transaction, Bienaime directly owns 7,450 Keros shares. The filing notes that the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the purchase was scheduled in advance rather than timed discretionarily.
Keros Therapeutics filed an 8-K describing new clinical steps for its lead drug candidate, rinvatercept. The company has entered into an agreement with Massachusetts General Hospital to design a Phase 2 trial of rinvatercept in amyotrophic lateral sclerosis within the biomarker-driven Healey ALS MyMatch program.
Keros also reported presenting additional data from a Phase 1 trial of rinvatercept in healthy volunteers. Rinvatercept was generally well tolerated and produced changes in body composition, including increased muscle mass, reduced fat mass and higher bone mineral density, along with proteomic evidence of target engagement and effects on fibrosis, inflammation and energy metabolism.
The company highlighted preclinical mouse data in Duchenne muscular dystrophy and ALS models, and reiterated plans to advance rinvatercept into two Phase 2 clinical trials, one in Duchenne muscular dystrophy and one in ALS.
Keros Therapeutics furnished an updated corporate presentation outlining its pipeline and a major partnership for elritercept. The company highlights rinvatercept (KER-065), a TGF-β ligand trap in Phase 2 planning for Duchenne muscular dystrophy, with additional plans to engage regulators on a Phase 2 trial in amyotrophic lateral sclerosis in the second half of 2026.
The deck also details elritercept (KER-050), licensed globally (excluding mainland China, Hong Kong and Macau) to Takeda. Keros received a $200 million upfront payment and is eligible for over $1.1 billion in development, approval and commercial milestones, plus tiered royalties from low double-digits to high teens. A global Phase 3 RENEW trial in lower-risk myelodysplastic syndromes is underway, with transfusion independence as the primary endpoint.